Home Covid News and Updates Govt planning to ramp up Covaxin production to 10 crore doses per month: VK Paul

Govt planning to ramp up Covaxin production to 10 crore doses per month: VK Paul

by Vaishali Sharma
NITI Aayog

With several states complaining of vaccine shortage, the Centre on Saturday stated that the plan is to ramp up the production of Bharat Biotech’s Covaxin in coming months. Currently, 1.5 crore doses are being produced every month and the intent is to increase the production to 10 crore doses monthly, the news agency ANI reported.

Dr. VK Paul, Member-Health, Niti Aayog, “Around 1.5 crore doses of Covaxin are being produced per month. The plan is to ramp up the production to 10 crore doses per month.”

Meanwhile, the Ministry of Science and Technology, earlier today, announced to provide a grant to increase the production of the indigenous vaccine.

In an official statement, the ministry said, “To augment the capacity of Indigenous production of Covaxin under the Mission, the Department of Biotechnology, Government of India in April, 2021 provided financial support as Grant to vaccine manufacturing facilities for enhanced production capacities, which is expected to reach more than 10 crore doses per month by September, 2021.”

“As a part of this augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufactures are being upgraded with required infrastructure and technology. Financial support is being provided as grant from GoI to the tune of approx. ₹65 crore to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production,” it added.

Earlier this week, Paul informed that Bharat Biotech is ready to share its technology with other manufacturers to ramp up the production amid the cry of vaccine shortage. Paul noted, “People say that Covaxin be given to other companies for manufacturing. I am happy to say that Covaxin manufacturing company (Bharat Biotech) has welcomed this when we discussed it with them. Under this vaccine live virus is inactivated & this is done only in BSL3 labs.”

“Not every company has this. We give an open invitation to companies who want to do this. Companies that want to manufacture Covaxin, should do it together. Govt will assist so that capacity is increased,” he said.

Taking the cue, Paul today said, “Tie-ups and technology transfer are complex process. Government is exploring areas or ways to scale up vaccine production.”

You may also like